LC-MF-4
Based on 1 Customer Validation
LC-MF-4 is an orally active VHL-recruiting FGFR3 PROTAC degrader and hERG potassium channel inhibitor. LC-MF-4 has an IC50 of 16.6 nM against human FGFR3, exhibits inhibitory activity against hERG potassium channels, suppresses the expression of genes related to mitochondrial biogenesis and ATP synthesis, inhibits cancer cell proliferation, and shows significant antitumor activity in mice. LC-MF-4 can be used in the research of bladder cancer, urothelial carcinoma, FGFR3Y373C mutant cancers, and FGFR3-TACC3 fusion-positive cancers.
(Pink: FGFR3 ligand (HY-160013); Blue: VHL ligand (HY-125905); Black: linker).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.46%
- Formel: C55H68Cl2FN11O8S
- Molecular Weight:1133.17
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Alle PROTACs Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
FGFR3 16.6 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RT-112 | IC50 |
28.98 nM
|
Antiproliferative activity against human RT112 cells assessed as reduction in cell viability incubated for 72 hrs by cell proliferation viability assay.
Antiproliferative activity against human RT112 cells assessed as reduction in cell viability incubated for 72 hrs by cell proliferation viability assay.
|
40575843 |
| KMS-11 | DC50 |
30.8 nM
|
Dose-dependent FGFR3 degradation in human myeloma KMS-11 cells (FGFR3 Y373C mutant) measured via Western blotting or immunofluorescence after 8 h treatment.
Dose-dependent FGFR3 degradation in human myeloma KMS-11 cells (FGFR3 Y373C mutant) measured via Western blotting or immunofluorescence after 8 h treatment.
|
40575843 |
| KMS-11 | IC50 |
25.6 nM
|
Antiproliferative activity against human myeloma KMS-11 cells (FGFR3 Y373C mutant) assessed as reduction in cell viability incubated for 72 hrs.
Antiproliferative activity against human myeloma KMS-11 cells (FGFR3 Y373C mutant) assessed as reduction in cell viability incubated for 72 hrs.
|
40575843 |
| BaF3 | IC50 |
7.03 nM
|
Antiproliferative activity against engineered Ba/F3-FGFR3-TACC3 cells assessed as reduction in cell viability incubated for 72 hrs.
Antiproliferative activity against engineered Ba/F3-FGFR3-TACC3 cells assessed as reduction in cell viability incubated for 72 hrs.
|
40575843 |
In Vitro
LC-MF-4 (0.01 nM-10 μM; 72 h) inhibits the proliferation of RT112 cells, with an IC50 value of 28.98 nM[1].
LC-MF-4 (0.1 nM-1 μM; 6-12 h) potently inhibits the activity of the purified FGFR3 kinase domain, with an IC50 of 16.6 nM[1].
LC-MF-4 (0.5 nM-10 μM; 6-12 h) potently and persistently degrades FGFR3 in KMS-11 cells harboring the FGFR3Y373C mutation, with a DC50 of 30.8 nM[1].
LC-MF-4 (500 nM; 8 h) exhibits excellent proteome selectivity for FGFR3 degradation in KMS-11 cells[1].
LC-MF-4 (20-1000 nM; 8 h) potently inhibits the activation of FGFR3 and its downstream signaling pathways in FGFR3Y373C-mutant KMS-11 cells[1].
LC-MF-4 (0.1-10 μM; 72 h) potently inhibits the proliferation of KMS-11 cells carrying the FGFR3Y373C mutation, with an IC50 of 25.6 nM, whereas it exerts no significant effects on non-FGFR3-driven cancer cells and normal cells[1].
LC-MF-4 (1-1000 nM; 8 h) degrades the FGFR3-TACC3 fusion protein and inhibits its kinase activity in engineered Ba/F3-FGFR3-TACC3 cells[1].
LC-MF-4 (1-100 nM; 72 h) potently inhibits the proliferation of Ba/F3 cells driven by the FGFR3-TACC3 fusion gene, with an IC50 of 7.03 nM[1].
LC-MF-4 (100 nM) potently inhibits colony formation of FGFR3-TACC3 fusion-positive RT112 bladder cancer cells[1].
LC-MF-4 (100 nM; 8 h) inhibits mitochondrial metabolism and biogenesis in FGFR3-TACC3 fusion-positive RT112 bladder cancer cells by downregulating the expression of key genes, ATP production, and PGC1α levels[1].
LC-MF-4 (100 nM; 6 h) potently degrades FGFR1 in NCI-H1581 cells and FGFR2 in KATO III cells[1].
LC-MF-4 (0.1-30 μM) exhibits extremely weak inhibitory activity against hERG potassium channels, with an inhibition rate of less than 25% at 30 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RT112
-
Concentration:0.01, 0.1, 1, 10,100 nM; 1, 10 μM
-
Incubation Time:72 h
-
Result:Inhibited RT112 cell viability in a concentration-dependent manner.
Achieved an IC50 value of 28.98 nM.
-
Cell Line:human myeloma KMS-11 cells (FGFR3 Y373C mutant)
-
Concentration:0.5, 1.5, 4.3, 13, 41, 123, 370, 1111, 10000 nM (dose-dependent degradation assay); 100 nM (time-course assay)
-
Incubation Time:8 h (dose-dependent degradation assay); 6 h, 8 h, 12 h (time-course assay)
-
Result:Induced dose-dependent FGFR3 degradation with a DC50 of 30.8 nM and a Dmax of 85% after 8 h treatment.
Reduced FGFR3 levels to 15% of control after 8 h treatment with 100 nM, and levels remained below 50% for 16 h post-washout.
Confirmed marked reduction of FGFR3 signal after 6 or 12 h treatment with 100 nM.
-
Cell Line:human myeloma KMS-11 cells (FGFR3 Y373C mutant)
-
Concentration:20, 100, 500, 1000 nM
-
Incubation Time:8 h
-
Result:Completely blocked FGF2-stimulated FGFR phosphorylation at 100 nM.
Significantly reduced phosphorylation of downstream signaling proteins FRS2α, PLCγ, and AKT compared to control.
-
Cell Line:human myeloma KMS-11 cells (FGFR3 Y373C mutant); NCI-H1975 cells; MV-4-11 cells; HEK293 cells
-
Concentration:0.1, 1, 10, 100 nM; 1, 10, 10 μM
-
Incubation Time:72 h
-
Result:Inhibited KMS-11 cell proliferation efficiently with an IC50 of 25.6 nM.
Showed no significant antiproliferative activity against NCI-H1975, MV-4-11, or HEK293 cells.
-
Cell Line:engineered Ba/F3-FGFR3-TACC3 cells
-
Concentration:1, 4, 12, 37, 111, 333, 1000 nM
-
Incubation Time:8 h
-
Result:Induced dose-dependent reduction of FGFR3-TACC3 fusion protein levels.
Decreased FGFR phosphorylation.
-
Cell Line:engineered Ba/F3-FGFR3-TACC3 cells
-
Concentration:1, 10, 100, 1000 nM
-
Incubation Time:72 h
-
Result:Potently inhibited Ba/F3-FGFR3-TACC3 cell proliferation with an IC50 of 7.03 nM.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (female, 6 weeks old)[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; once daily for 14 days
-
Result:Achieved 50.2% tumor growth inhibition.
Significantly reduced final tumor weight compared to vehicle control.
Significantly reduced FGFR3-TACC3 protein levels in tumor lysates.
Showed superior inhibition of downstream protein phosphorylation (PLCγ, AKT, ERK1/2) compared to LC-CS-4.
Caused no significant body weight loss or adverse effects during treatment.
Chemical Information
-
Appearance Solid
-
Molecular Weight 1133.17
-
Formel C55H68Cl2FN11O8S
-
Color White to off-white
-
SMILES
COC1=CC(OC)=C(C(NC(N(C2=NC=NC(NC3=CC=C(C=C3)N4CCN(CC4)CCCCCOC5=CC(C6=C(N=CS6)C)=CC=C5CNC([C@@H]7C[C@H](CN7C([C@H](C(C)(C)C)NC(C8(CC8)F)=O)=O)O)=O)=C2)C)=O)=C1Cl)Cl
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (88.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Reinheit & Dokumentation
-
Data Sheet (287 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8825 mL | 4.4124 mL | 8.8248 mL | 22.0620 mL |
| 5 mM | 0.1765 mL | 0.8825 mL | 1.7650 mL | 4.4124 mL | |
| 10 mM | 0.0882 mL | 0.4412 mL | 0.8825 mL | 2.2062 mL | |
| 15 mM | 0.0588 mL | 0.2942 mL | 0.5883 mL | 1.4708 mL | |
| 20 mM | 0.0441 mL | 0.2206 mL | 0.4412 mL | 1.1031 mL | |
| 25 mM | 0.0353 mL | 0.1765 mL | 0.3530 mL | 0.8825 mL | |
| 30 mM | 0.0294 mL | 0.1471 mL | 0.2942 mL | 0.7354 mL | |
| 40 mM | 0.0221 mL | 0.1103 mL | 0.2206 mL | 0.5516 mL | |
| 50 mM | 0.0176 mL | 0.0882 mL | 0.1765 mL | 0.4412 mL | |
| 60 mM | 0.0147 mL | 0.0735 mL | 0.1471 mL | 0.3677 mL | |
| 80 mM | 0.0110 mL | 0.0552 mL | 0.1103 mL | 0.2758 mL |